Follicular Lymphoma, Marginal Zone Lymphoma
Conditions
Keywords
Stage I-II, Radiotherapy, 25-089
Brief summary
The researchers are doing this study to find out whether a very low dose of radiation therapy (VLDRT) is an effective treatment for people with follicular lymphoma (FL) or marginal zone lymphoma (MZL) and works as well as the standard dose of radiation therapy. The researchers will see if VLDRT works against cancer in the area that is currently affected by cancer and if the therapy prevents new spots of lymphoma from developing. The researchers will also compare VLDRT with the standard dose of radiation therapy to see if VLDRT causes fewer side effects. Radiation therapy uses beams of intense energy to kill cancer cells. Standard doses of radiation therapy can cause short- and long-term side effects. Researchers think VLDRT may be as effective as standard doses, and, because VLDRT uses less radiation, researchers think VLDRT may cause fewer side effects than standard doses.
Interventions
RADIATIONRadiation (Standard)
24 Gy in 12 fractions
RADIATIONRadiation (Very low dose)
4 Gy in 1-2 consecutive daily fractions
Sponsors
Memorial Sloan Kettering Cancer Center
The Leukemia and Lymphoma Society
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
This a phase III, randomized, multi-center non-inferiority trial.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
(Arms 1\&2) * Patients must be diagnosed with a follicular lymphoma or marginal zone lymphoma. Of note, there are now two widely-utilized pathology classification criteria used for mature B-cell lymphomas, the World Health Organization (WHO) 5th Edition Classification of Lymphoid Neoplasms and the International Consensus Classification (ICC) of Mature Lymphoid Neoplasms. Either criteria is acceptable and for the purposes of this protocol, the following diagnoses are included: * Follicular lymphoma * WHO 5th Edition * Classic follicular lymphoma (cFL) * Follicular lymphoma with uncommon features (uFL) * Pediatric type follicular lymphoma * Duodenal type follicular lymphoma * ICC * Follicular lymphoma, grades 1-2 or 3A * BCL2 rearrangement negative, CD23 positive follicle center lymphoma * Pediatric type follicular lymphoma * Duodenal type follicular lymphoma * Marginal zone lymphoma * WHO 5th Edition and ICC * Nodal marginal zone lymphoma * Pediatric nodal marginal zone lymphoma * Extranodal marginal zone lymphoma of mucosa associated lymphoid tissue (MALT) * Patients must have stage I or II disease (with stage I defined as involvement of one nodal region and stage II as two or more nodal regions involved on the same side of the diaphragm) * Patients should be newly diagnosed or previously observed with no prior lymphoma-directed therapy * If the patient is referred for localized gastric MALT lymphoma, there should be documented negative H. Pylori testing within 6 months prior to proposed radiotherapy * Age at the time of enrollment of ≥18 years * Patients must be able to start radiation within 2 months from time of randomization
Exclusion criteria
* Prior radiation to site(s) needing treatment * Follicular lymphoma, grade 3B (ICC) or Follicular large B cell lymphoma (FLBL by WHO 5th edition criteria) * Patients planned to receive concurrent systemic therapy (including oral steroids) for their lymphoma * Patient has cutaneous only iNHL defined as primary cutaneous B-cell lymphoma, primary cutaneous follicle center lymphoma, cutaneous marginal zone lymphoma or unspecified indolent lymphoma of the skin * Gross total resection of all disease * Tumor size measuring ≥5 cm in maximum diameter on any modality diagnostic imaging * Patients with any concurrent medical or psychiatric condition or disease which, in the investigator's judgment, would make them inappropriate candidates for entry into this study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| progression-free survival | 2 years | Progression will be defined as either PD as per Lugano criteria (either treated or non-treated lesions) OR * Receipt of any additional radiotherapy for lymphoma to an initially involved site outside of the protocol mandated treatment OR * Death from any cause |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| radiographic response | 6 months | using Lugano criteria |
Countries
United States
Contacts
CONTACTBrandon Imber, MD
CONTACTJoachim Yahalom, MD
PRINCIPAL_INVESTIGATORBrandon Imber, MD
Memorial Sloan Kettering Cancer Center
Outcome results
None listed